CA-VISA-INC.
11.7.2024 22:08:28 CEST | Business Wire | Press release
With the Opening Ceremony in Paris about two weeks away, Visa (NYSE: V), the Worldwide Payment Technology Partner of the Olympic and Paralympic Games, today announced its final roster of 147 Team Visa athletes for Paris 2024. Visa also shares ways to connect fans to the spirit of Paris 2024, both for those in attendance and those who want to participate at home.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711202801/en/
Team Visa Olympic and Paralympic Games Paris 2024 (Photo: Business Wire)
“As the Worldwide Payment Technology Partner of the Olympic and Paralympic Games, we’re excited to integrate Visa products and platforms that create value for both the athlete and fan experience during Paris 2024,” said Frank Cooper, CMO, Visa. “The Team Visa athletes preparing to compete in the Olympic and Paralympic Games Paris 2024 have consistently taken small steps over many years to reach this goal. We have supported these incredible athletes in their quest and want to help share their journeys with the world.”
Introducing Team Visa for Paris 2024
Founded in 2000, Team Visa has championed nearly 700 athletes over the last quarter century – each selected because of their athletic achievements, community involvement, and alignment with Visa’s core values of equality, access, and inclusion. Team Visa for Paris 2024 includes decorated Olympians and Paralympians like Simone Biles (USA, Gymnastics), Sky Brown (Great Britain, Skateboarding), Noah Lyles (USA, Athletics - Sprint) and Raissa Rocha Machado (Brazil, Para Athletics - Javelin) as well as first-timers like Shigeyuki Nakarai (Japan, Breaking) and Goodness Nwachukwu (Nigeria, Para Athletics - Discus). Team Visa also welcomes refugee athlete Dina Pouryounes (Taekwondo), forced to flee her homeland in the North of Iran to find refuge in The Netherlands.
“Visa has always been committed to empowering athletes on and off the track and it is great to see that in action,” said Noah Lyles. “I’m looking forward to getting in the blocks in Paris and putting it all out there. I have so much gratitude for my support system who has been with me every step of the way, including Team Visa.”
Team Visa by-the-numbers
- 147 athletes representing 67 countries, 40 sports, including the new Breaking competition, making this Visa’s largest, most diverse roster yet, and with 46 Paralympic athletes and hopefuls, our largest Paralympic roster to date
- 80 female and 67 male – underscoring Visa’s commitment to inclusion in sport
- Record breakers and world #1s like Iga Świątek (Poland, Tennis), PV Sindhu (India, Badminton), and Simone Biles (USA, Gymnastics)
- Newcomers and veterans alike, such as first-timers Qingyi Liu (China, Breaking) and Alexia Putellas (Spain, Football) and returners Kanoa Igarashi (Japan, Surfing) and Adam Peaty (Great Britain, Swimming)
Engaging fans in Paris and around the world
In the spirit of the theme “Pas Sans Vous,” or “Not Without You,” Visa is taking action to ensure everyone, everywhere can participate in Paris 2024:
- Visa Go, a new mobile application for Visa cardholders visiting the Olympic and Paralympic Games Paris 2024, offers access to unique experiences and exclusive content, spotlights Team Visa athletes and shares their progress during Paris 2024. The app will also offer a curated selection of discounts and offers from official partners and local shops and restaurants. Fans can purchase a virtual Visa prepaid card through Visa Go, if needed.
- Blending sports with culture, Visa has commissioned six global artists to create works of art to appear on billboards throughout Paris and other nearby host cities celebrating Paris 2024 and highlighting local commerce. In a tribute to Paris, the global capital for street art, pieces will appear on billboards in train stations, airports, the metro, and elsewhere around the cities to help support and promote local small businesses, who contribute to the city’s vitality. Participating artists include leading street artist from Seine-Saint-Denis Marko 93 (France); influential street artist and activist Swoon (USA); pioneering graffiti artist JonOne (USA); native Parisian artist Olivia De Bona (France); prolific colorblind street artist Alex Senna (Brazil); and multidisciplinary artist Vexta (Australia).
- A custom payment services solution that Visa has implemented for Paris 2024 will bring seamless contactless payment acceptance to 3,500 points of sale across 32 Olympic venues and 16 Paralympic venues.
- In recognition of Visa’s long-standing partnership with the Olympic and Paralympic Games, Paris 2024 proudly accepts only Visa for card and mobile payments, along with cash, at Olympic and Paralympic venues as well as the flagship Paris 2024 Megastore on Paris’ iconic Champs-Élysées and other official merchandise shops around France. Visa is also the Official Way to Pay for official merchandise online at the Olympic Shop.
- Fans can join the fun on Roblox at Olympic World presented by Visa, a new immersive experience that features a unique collection of sports-themed activities, quests, and fun facts.
In the Paris metro area, “Pas Sans Vous” will come to life through Visa’s commitment to giving back to local youth and small business. Visa has partnered with youth sports program Sport Dans La Ville, providing hundreds of tickets to Paris 2024 for program participants, funding new sports centers and a girls mentorship program, as well as a development program for young journalists with Le Monde, one of France’s top news platforms. Additionally, Visa invited small businesses across France to participate in the “Les Paiements Gagnants,” or “Winning Payments” national promotion, in which more than 25,000 small businesses opted in to offer Visa cardholders a chance to win Paris 2024 tickets, helping small businesses to benefit more from the commercial opportunities that the Olympic and Paralympic Games bring.
Learn more about Visa’s commitment to the Olympic and Paralympic Games here.
About Visa
Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711202801/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom